Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05459727
Other study ID # NFEC-2022-243
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2022
Source Nanfang Hospital of Southern Medical University
Contact Jiancheng Xiu, MD
Phone +86-020-61648319
Email xiujch@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate whether non-surgical periodontal therapy can help to control the cardiovascular risk among patients with moderate/severe periodontitis and at risk of cardiovascular disease.


Description:

Previous studies showed that the treatment of periodontitis can partially improve the control of risk factors of cardiovascular disease (e.g. blood pressure, interleukin 6), whereas the evidence is still limited. Moreover, there is currently no study reporting the impact of periodontal treatment on the overall risk of cardiovascular disease. The prevalence of periodontitis in China was 62.4%. In clinical practice, a large number of patients with moderate/severe periodontitis and at risk of cardiovascular disease seek medical advice. However, the existing guidelines lack relevant recommendations. Therefore, this study intends to evaluate whether non-surgical periodontal therapy can help to control cardiovascular risk. 376 patients with moderate/severe periodontitis and at risk of cardiovascular disease will be randomized. Those randomized to the intervention arm will receive non-surgical periodontal therapy which includes full-mouth subgingival scaling and root planing. Those randomized to the control arm will receive supragingival ultrasonic scaling. All patients were given instructions on basic oral hygiene.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 376
Est. completion date December 31, 2026
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years; - At risk of cardiovascular disease (defined as "Framingham Score" predicted 10-year risk of cardiovascular disease = 20%); - Moderate//severe periodontitis; Exclusion Criteria: - Cardiovascular diseases at baseline (coronary heart disease, stroke and peripheral artery disease); - Received periodontal treatment within the past 6 months; - Pregnant or lactating females; - Non residents of Guangzhou and its surrounding cities or expected to leave Guangzhou or its surrounding cities within 1 year; - Malignant tumors or other end-stage diseases with life expectancy less than 1 year; - End-stage renal disease; - Patients with high bleeding risk, high blood pressures or other situations that make them unable to receive interventions; - Refuse to provide informed consent;

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Non-surgical periodontal therapy
Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.
Control periodontal treatment
Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.

Locations

Country Name City State
China Nanfang Hospital, Southern Medical University Guangzhou Guangdong
China Stomatological Hospital, Southern Medical University Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Nanfang Hospital of Southern Medical University Stomatological Hospital, Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Cardiovascular risk (Framingham risk score (FRS)) at 1 year. Cardiovascular risk is assessed by "Framingham risk score (FRS)". (Circulation, 2008,117(6): 743-753.) Generally, the "Framingham risk score (FRS)" ranges from -4 to 33 for men and -5 to 33 for women. A higher "Framingham risk score (FRS)" means a higher risk of developing cardiovascular disease. Baseline; 1 year
Secondary Change from baseline systolic blood pressure at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline diastolic blood pressure at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline fasting blood glucose at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline glycosylated hemoglobin at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline total cholesterol at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline triglyceride at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline low-density lipoprotein cholesterol at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline high-density lipoprotein cholesterol at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline high sensitivity C-reactive protein at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline interleukin-6 at 1 year after enrollment. Baseline; 1 year
Secondary Change from baseline cardiovascular risk (CHINA-PAR) at 1 year after enrollment. China-PAR is an abbreviation of "Prediction for ASCVD Risk in China". It is a prediction model developed by YANG X. (Circulation, 2016,134(19):1430-1440.) Through China-PAR, the investigators can assess one's cardiovascular risk in 10 years. The result of China-PAR is directly one's predicted cardiovascular risk in 10 years, ranging from 0% - 100%, with a higher probability meaning a higher risk of cardiovascular disease. Baseline; 1 year
Secondary Change from baseline community periodontal index at 1 year after enrollment. Community periodontal index will be evaluated according to the guidelines by stomatologists. The community periodontal index ranges from 0 - 4 points for each tooth. Higher points mean more severe periodontitis. Baseline; 1 year
Secondary Major adverse cardiovascular event The major adverse cardiovascular event includes acute myocardial infarction, stroke, heart failure, peripheral artery disease, and coronary heart disease. Baseline; 3 months; 6 months; 9 months; 1 year; 2 years; 3 years;
Secondary All-cause mortality Defined as any death after enrollment. Baseline; 3 months; 6 months; 9 months; 1 year; 2 years; 3 years;
Secondary Change from baseline anxiety at 1 year after enrollment. Anxiety will be assessed through "Self-Rating Anxiety Scale (SAS)". The SAS score range from 20 - 80 points. Higher points mean more serious anxiety. Baseline; 1 year
Secondary Change from baseline pain at 1 year after enrollment. The degree of pain will be assessed through "Visual Analogue Scale (VAS)". The VAS score range from 0 - 10 points. Higher points mean more serious pain. Baseline; 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)